DZ3376A1 - Formulations stabilisees de 6-hydroxy-3-(4-[2-(piperidin-1-yl) ethoxy]phenoxy)-2-(4-methoxyphenyl) benzo[b]thiophene et sels de ces composes - Google Patents

Formulations stabilisees de 6-hydroxy-3-(4-[2-(piperidin-1-yl) ethoxy]phenoxy)-2-(4-methoxyphenyl) benzo[b]thiophene et sels de ces composes

Info

Publication number: DZ3376A1
Authority: DZ; Algeria
Prior art keywords: piperidin; thiophene; benzo; methoxyphenyl; phenoxy
Prior art date: 2000-05-08

Application number

DZ013376A

Other languages

English (en)

Inventor

Fadia Najjar Bashore

Kerry John Hartauer

Michael Dean Minnett

Eugene Clark Rickard

Cheryl Ann Tingle

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-05-08

Filing date

2001-04-30

Publication date

2001-11-15

2001-04-30 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2001-11-15 Application granted granted Critical

2001-11-15 Publication of DZ3376A1 publication Critical patent/DZ3376A1/fr

Links

MCGDSOGUHLTADD-UHFFFAOYSA-N arzoxifene Chemical compound C1=CC(OC)=CC=C1C1=C(OC=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 MCGDSOGUHLTADD-UHFFFAOYSA-N 0.000 title 1
239000000203 mixture Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Physical Education & Sports Medicine (AREA)
Epidemiology (AREA)
Rheumatology (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Orthopedic Medicine & Surgery (AREA)
Heart & Thoracic Surgery (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Diabetes (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Obesity (AREA)
Hematology (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Endocrinology (AREA)
Toxicology (AREA)
Reproductive Health (AREA)
Psychiatry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Oil, Petroleum & Natural Gas (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

DZ013376A 2000-05-08 2001-04-30 Formulations stabilisees de 6-hydroxy-3-(4-[2-(piperidin-1-yl) ethoxy]phenoxy)-2-(4-methoxyphenyl) benzo[b]thiophene et sels de ces composes DZ3376A1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US20323500P	2000-05-08	2000-05-08
PCT/US2001/011736 WO2001085147A2 (fr)	2000-05-08	2001-04-30	Formulations stabilisees de 6-hydroxy-3-(4-[2-(piperidin-1-yl) ethoxy]phenoxy)-2-(4-methoxyphenyl) benzo[b]thiophene et sels de ces composes

Publications (1)

Publication Number	Publication Date
DZ3376A1 true DZ3376A1 (fr)	2001-11-15

Family

ID=22753086

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DZ013376A DZ3376A1 (fr)	2000-05-08	2001-04-30	Formulations stabilisees de 6-hydroxy-3-(4-[2-(piperidin-1-yl) ethoxy]phenoxy)-2-(4-methoxyphenyl) benzo[b]thiophene et sels de ces composes

Country Status (30)

Country	Link
EP (1)	EP1357903B1 (fr)
JP (1)	JP2003535827A (fr)
KR (1)	KR100806992B1 (fr)
CN (1)	CN1283250C (fr)
AR (1)	AR028401A1 (fr)
AT (1)	ATE348605T1 (fr)
AU (2)	AU5531001A (fr)
BR (1)	BR0110620A (fr)
CA (2)	CA2691739A1 (fr)
CZ (1)	CZ20023651A3 (fr)
DE (1)	DE60125416T2 (fr)
DZ (1)	DZ3376A1 (fr)
EA (1)	EA004871B1 (fr)
EC (1)	ECSP014066A (fr)
EG (1)	EG24223A (fr)
ES (1)	ES2276784T3 (fr)
HR (1)	HRP20020883A2 (fr)
HU (1)	HUP0302190A3 (fr)
IL (2)	IL152699A0 (fr)
MX (1)	MXPA02010923A (fr)
NO (1)	NO20025219L (fr)
NZ (1)	NZ521393A (fr)
PE (1)	PE20011255A1 (fr)
PL (1)	PL365472A1 (fr)
SK (1)	SK286346B6 (fr)
SV (1)	SV2002000435A (fr)
TW (1)	TWI225787B (fr)
UA (1)	UA77941C2 (fr)
WO (1)	WO2001085147A2 (fr)
ZA (1)	ZA200207651B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6653479B1 (en)	1999-07-29	2003-11-25	Eli Lilly And Company	Crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b] thiophene hydrochloride
US6610706B1 (en)	1999-07-29	2003-08-26	Eli Lilly And Company	Crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride
US20070066578A1 (en) *	2003-09-22	2007-03-22	Noboru Shimizu	5-Aminosalicylic acid solid preparation improved in discoloration and method of storing the same
WO2016024369A1 (fr) *	2014-08-13	2016-02-18	テバ製薬株式会社	Composition médicinale pour le traitement du cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PE44597A1 (es) *	1995-02-28	1997-10-13	Lilly Co Eli	Compuestos de benzotiofeno, productos intermedios, composiciones y procedimientos
ZA982877B (en) *	1997-04-09	1999-10-04	Lilly Co Eli	Treatment of central nervous system disorders with selective estrogen receptor modulators.
ES2208384T3 (es) *	1999-07-29	2004-06-16	Eli Lilly And Company	Forma cristalina de clorhidrato de 6 hidroxi-3-(4-(2-(piperidin-1-il)-etoxi)-fenoxi)2--(4-metoxifenil)-benzo(b)tiofeno.
EP1204656A2 (fr) *	1999-07-29	2002-05-15	Eli Lilly And Company	NOUVELLE FORME CRISTALLINE DE CHLORHYDRATE DE 6-HYDROXY-3-(4- 2-(PIPERIDIN-1-YL)ETHOXY]PHENOXY)-2-(4-METHOXYPHENYL)BENZO b]THIOPHENE
AU780211B2 (en) *	1999-07-29	2005-03-10	Eli Lilly And Company	Crystalline form of 6-hydroxy-3-(4-(2-(piperidin-1-yl) ethoxy)phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride

2001
- 2001-04-30 AT AT01928454T patent/ATE348605T1/de not_active IP Right Cessation
- 2001-04-30 CA CA002691739A patent/CA2691739A1/fr not_active Abandoned
- 2001-04-30 UA UA2002118788A patent/UA77941C2/uk unknown
- 2001-04-30 AU AU5531001A patent/AU5531001A/xx active Pending
- 2001-04-30 ES ES01928454T patent/ES2276784T3/es not_active Expired - Lifetime
- 2001-04-30 CZ CZ20023651A patent/CZ20023651A3/cs unknown
- 2001-04-30 KR KR1020027014923A patent/KR100806992B1/ko not_active Expired - Fee Related
- 2001-04-30 IL IL15269901A patent/IL152699A0/xx unknown
- 2001-04-30 PL PL01365472A patent/PL365472A1/xx not_active Application Discontinuation
- 2001-04-30 HU HU0302190A patent/HUP0302190A3/hu unknown
- 2001-04-30 HR HR20020883A patent/HRP20020883A2/hr not_active Application Discontinuation
- 2001-04-30 CA CA002408563A patent/CA2408563A1/fr not_active Abandoned
- 2001-04-30 WO PCT/US2001/011736 patent/WO2001085147A2/fr not_active Ceased
- 2001-04-30 EP EP01928454A patent/EP1357903B1/fr not_active Expired - Lifetime
- 2001-04-30 DZ DZ013376A patent/DZ3376A1/fr active
- 2001-04-30 DE DE60125416T patent/DE60125416T2/de not_active Expired - Fee Related
- 2001-04-30 EA EA200201186A patent/EA004871B1/ru not_active IP Right Cessation
- 2001-04-30 AU AU2001255310A patent/AU2001255310C1/en not_active Ceased
- 2001-04-30 CN CNB018091296A patent/CN1283250C/zh not_active Expired - Fee Related
- 2001-04-30 MX MXPA02010923A patent/MXPA02010923A/es active IP Right Grant
- 2001-04-30 JP JP2001581801A patent/JP2003535827A/ja active Pending
- 2001-04-30 NZ NZ521393A patent/NZ521393A/en unknown
- 2001-04-30 SK SK1565-2002A patent/SK286346B6/sk not_active IP Right Cessation
- 2001-04-30 BR BR0110620-1A patent/BR0110620A/pt not_active Application Discontinuation
- 2001-05-02 TW TW090110500A patent/TWI225787B/zh not_active IP Right Cessation
- 2001-05-02 AR ARP010102074A patent/AR028401A1/es unknown
- 2001-05-04 PE PE2001000402A patent/PE20011255A1/es not_active Application Discontinuation
- 2001-05-05 EG EG20010461A patent/EG24223A/xx active
- 2001-05-07 SV SV2001000435A patent/SV2002000435A/es not_active Application Discontinuation
- 2001-05-08 EC EC2001004066A patent/ECSP014066A/es unknown
2002
- 2002-09-23 ZA ZA200207651A patent/ZA200207651B/en unknown
- 2002-10-31 NO NO20025219A patent/NO20025219L/no not_active Application Discontinuation
- 2002-11-07 IL IL152699A patent/IL152699A/en not_active IP Right Cessation

Also Published As

Publication number	Publication date
HK1061349A1 (en)	2004-09-17
HUP0302190A3 (en)	2009-03-30
MXPA02010923A (es)	2003-03-27
JP2003535827A (ja)	2003-12-02
WO2001085147A2 (fr)	2001-11-15
NO20025219D0 (no)	2002-10-31
IL152699A (en)	2009-09-01
CZ20023651A3 (cs)	2003-02-12
CA2408563A1 (fr)	2001-11-15
CN1283250C (zh)	2006-11-08
EP1357903B1 (fr)	2006-12-20
ES2276784T3 (es)	2007-07-01
AU2001255310B8 (en)	2005-03-10
AR028401A1 (es)	2003-05-07
ATE348605T1 (de)	2007-01-15
DE60125416D1 (de)	2007-02-01
KR20030009477A (ko)	2003-01-29
AU2001255310C1 (en)	2006-03-09
PL365472A1 (en)	2005-01-10
ECSP014066A (es)	2002-02-25
AU2001255310B2 (en)	2005-03-03
WO2001085147A3 (fr)	2003-08-28
EP1357903A2 (fr)	2003-11-05
UA77941C2 (en)	2007-02-15
AU5531001A (en)	2001-11-20
EA200201186A1 (ru)	2003-08-28
SK286346B6 (en)	2008-07-07
HRP20020883A2 (en)	2005-02-28
KR100806992B1 (ko)	2008-02-25
NZ521393A (en)	2004-08-27
ZA200207651B (en)	2003-12-23
EG24223A (en)	2008-11-10
SK15652002A3 (sk)	2003-04-01
PE20011255A1 (es)	2001-12-11
IL152699A0 (en)	2003-06-24
NO20025219L (no)	2002-10-31
SV2002000435A (es)	2002-10-24
DE60125416T2 (de)	2007-09-27
CN1545413A (zh)	2004-11-10
CA2691739A1 (fr)	2001-11-15
HUP0302190A2 (hu)	2003-10-28
TWI225787B (en)	2005-01-01
EA004871B1 (ru)	2004-08-26
BR0110620A (pt)	2003-04-01

Publication	Publication Date	Title
DE60005693D1 (de)	2003-11-06	Eine kristalline form von 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophen-hydrochlorid
NO20003879L (no)	2001-01-30	En ny krystallinsk form av 6-hydroksy-3-(4-[2-(piperidin-1- yl)etoksy] fenoksy)-2-(4-metoksyfenyl)benzo[b]tiofen hydroklorid
DZ3376A1 (fr)	2001-11-15	Formulations stabilisees de 6-hydroxy-3-(4-[2-(piperidin-1-yl) ethoxy]phenoxy)-2-(4-methoxyphenyl) benzo[b]thiophene et sels de ces composes
HUP0301403A3 (en)	2009-05-28	A novel crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride and it's use
HK1059258A (en)	2004-06-25	A crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride
ZA200003838B (en)	2002-01-28	A novel chrystalline form of 6-hydroxy-3-(4-[2-)piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride.
ZA200003837B (en)	2002-01-28	A novel chrystalline form of 6-hydroxy-3-(4-[2-)piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride.
TJ398B (en)	2004-12-29	A novel crystalline form of 6-hydroxy -3-(4-Ä2-(piperidin-1-yl) ethoxyÜ-phenoxy) -2-(4-methoxyphenyl) benzo ÄbÜ thiophene hydrochloride.